DK3463436T3 - Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling - Google Patents

Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling Download PDF

Info

Publication number
DK3463436T3
DK3463436T3 DK17729078.0T DK17729078T DK3463436T3 DK 3463436 T3 DK3463436 T3 DK 3463436T3 DK 17729078 T DK17729078 T DK 17729078T DK 3463436 T3 DK3463436 T3 DK 3463436T3
Authority
DK
Denmark
Prior art keywords
vaccine
cancer
treatment
combination
immune checkpoint
Prior art date
Application number
DK17729078.0T
Other languages
English (en)
Inventor
Gustav Gaudernack
Audun Tornes
Original Assignee
Ultimovacs Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultimovacs Asa filed Critical Ultimovacs Asa
Application granted granted Critical
Publication of DK3463436T3 publication Critical patent/DK3463436T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
DK17729078.0T 2016-06-02 2017-06-02 Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling DK3463436T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16172760 2016-06-02
PCT/EP2017/063589 WO2017207814A1 (en) 2016-06-02 2017-06-02 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

Publications (1)

Publication Number Publication Date
DK3463436T3 true DK3463436T3 (da) 2023-12-18

Family

ID=56132759

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17729078.0T DK3463436T3 (da) 2016-06-02 2017-06-02 Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling

Country Status (14)

Country Link
US (2) US11419927B2 (da)
EP (2) EP4253419A2 (da)
JP (2) JP7321709B2 (da)
AU (1) AU2017275782A1 (da)
CA (1) CA3026172A1 (da)
DK (1) DK3463436T3 (da)
ES (1) ES2965957T3 (da)
FI (1) FI3463436T3 (da)
LT (1) LT3463436T (da)
PL (1) PL3463436T3 (da)
PT (1) PT3463436T (da)
RS (1) RS65007B1 (da)
SI (1) SI3463436T1 (da)
WO (1) WO2017207814A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2536830T (lt) 2010-02-16 2019-11-11 Ultimovacs Asa Polipeptidai
GB201803178D0 (en) * 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
MA53026A (fr) * 2018-06-29 2021-05-05 Taiho Pharmaceutical Co Ltd Agent antitumoral et sa méthode d'évaluation
CN117940152A (zh) 2021-06-09 2024-04-26 阿尔特有限公司 缀合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0013542A (pt) 1999-08-23 2002-05-14 Dana Farber Cancer Inst Inc Moléculas b7-4 e usos para as mesmas
ES2629683T3 (es) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, una nueva molécula inmunorreguladora
CN1652820A (zh) 2002-04-12 2005-08-10 梅达雷克斯公司 使用ctla－4抗体的治疗方法
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
PL2439273T3 (pl) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
RS54271B1 (en) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
LT2536830T (lt) 2010-02-16 2019-11-11 Ultimovacs Asa Polipeptidai
WO2012037551A2 (en) 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
US9561266B2 (en) 2012-08-31 2017-02-07 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
GB201223386D0 (en) 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
AU2014220957A1 (en) 2013-02-22 2015-07-30 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
EA201992251A1 (ru) 2013-03-15 2020-05-08 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Противораковые вакцины и способы лечения с их применением
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
US20170035864A1 (en) 2013-12-09 2017-02-09 Bullet Biotechnology, Inc. SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
WO2015096811A1 (zh) 2013-12-27 2015-07-02 厦门松霖科技有限公司 暗装预埋组件
JP6581101B2 (ja) 2014-02-14 2019-09-25 イミューン デザイン コーポレイション 局所免疫刺激及び全身免疫刺激の組み合わせによる癌の免疫療法
WO2015128313A1 (en) 2014-02-25 2015-09-03 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
KR102499737B1 (ko) 2014-05-13 2023-02-13 버베리안 노딕 에이/에스 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법
AU2015259516B2 (en) 2014-05-13 2020-05-28 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
WO2016004213A2 (en) 2014-07-01 2016-01-07 Vicus Therapeutics, Llc Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
US20170196952A1 (en) 2014-07-07 2017-07-13 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016007499A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
EP3169699A4 (en) 2014-07-18 2018-06-20 The University of Washington Cancer vaccine compositions and methods of use thereof
EP3169355A4 (en) 2014-07-18 2018-07-25 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
AU2015334468B2 (en) 2014-10-23 2021-06-17 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
JP7305300B2 (ja) 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies

Also Published As

Publication number Publication date
CA3026172A1 (en) 2017-12-07
ES2965957T3 (es) 2024-04-17
LT3463436T (lt) 2024-01-25
RS65007B1 (sr) 2024-01-31
JP2019517508A (ja) 2019-06-24
WO2017207814A1 (en) 2017-12-07
US20230049012A1 (en) 2023-02-16
JP7321709B2 (ja) 2023-08-07
AU2017275782A1 (en) 2019-01-24
PL3463436T3 (pl) 2024-03-04
SI3463436T1 (sl) 2024-02-29
US20190247482A1 (en) 2019-08-15
JP2022171684A (ja) 2022-11-11
EP3463436A1 (en) 2019-04-10
EP3463436B1 (en) 2023-09-20
US11419927B2 (en) 2022-08-23
EP4253419A2 (en) 2023-10-04
PT3463436T (pt) 2023-12-28
FI3463436T3 (fi) 2023-12-04

Similar Documents

Publication Publication Date Title
IL286282A (en) Use of palinabolin in combination with immune checkpoint inhibitors
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3500299T3 (da) Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
DK3535392T3 (da) Immunologisk synlige celleoverfladevarianter til anvendelse i celleterapi
IL247841B (en) Heterocyclic compounds in combination with immune barrier therapy for use in the treatment of disorders mediated by pi3k gamma
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
IL265274A (en) Combined treatment of antibody and checkpoint inhibitor
DK3277842T3 (da) Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
BR112017002511A2 (pt) sistemas e métodos de almofada terapêutica
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3182996T3 (da) Fremgangsmåder til behandling af myelomatose med immunmodulatoriske forbindelser i kombination med antistoffer
HK1254954A1 (zh) Lpt-723和免疫檢查點抑制劑組合物及其治療方法
DK3532067T3 (da) Liposomal formulering til anvendelse til behandling af cancer
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3230318T3 (da) Immune checkpoint-inhibitor-kombinationer
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
EA201891679A1 (ru) Лечение рака онколитическим вирусом в комбинации с ингибитором контрольных точек
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3463436T3 (da) Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling
DK3408265T3 (da) Terapeutiske forbindelser
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer
DK2984184T3 (da) Anvendelse af dnq eller dnq-87 i kombination med en parp1-inhibitor til behandlingen af cancer
DK3153511T3 (da) 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
IL266116A (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use